Credit Suisse’s Opus Genetics IRD Stock Holding History

Credit Suisse’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,550	Closed	-$18K	–	4168
2020 Q1	$18K	Buy	+2,550	New	+$22.2K	﹤0.01%	3942
2014 Q3	–	Sell	-24	Closed	-$10K	–	4683
2014 Q2	$10K	Sell	24 -415	-95%	-$189K	﹤0.01%	4637
2014 Q1	$227K	Buy	+439	New	+$237K	﹤0.01%	4285
2013 Q3	–	Sell	-35	Closed	-$7K	–	4397
2013 Q2	$7K	Buy	+35	New	+$6.01K	﹤0.01%	4148

Other funds holding IRD

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Credit Suisse's IRD Position: Q2 2020 in Review

Credit Suisse sold out of Opus Genetics (IRD) in Q2 2020, closing a stake of 2,550 shares — an estimated $18K sold.

Credit Suisse first reported a position in IRD in Q2 2013 and held it in 4 quarters. The position peaked at $227K in Q1 2014. 14 funds tracked by Wall St. Rank hold IRD as of Q2 2020.

Credit Suisse reported no remaining Opus Genetics position as of Q2 2020 after selling out during the quarter.
Credit Suisse sold 2,550 Opus Genetics shares in Q2 2020, an estimated $18K.
Credit Suisse first reported a position in Opus Genetics in Q2 2013 and held it in 4 quarters.
Credit Suisse's Opus Genetics position peaked at $227K in Q1 2014.
14 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2020.

Based on Credit Suisse's 13F filing for Q2 2020, filed 12 Aug 2020.